Hongsheng Wu

Journal Articles

• Lew, R., Wu, H. (in press). A Simple Way to Program Power Calculations. Citeseer.
• Schechter, M., Anaya, N., Arteaga-Solis, E., Bagal, S., Morlando Geiger, J., McGarry, L., Oster, G., Van Brunt, K., Weycker, D., Wu, H. (in press). Impact of elexacaftor/tezacaftor/ivacaftor on healthcare resource utilization and costs among people with cystic fibrosis aged>= 12 years in the US: A retrospective analysis using commercial and Medicaid claims databases. Journal of Managed Care and Specialty Pharmacy. Page: S89--S89.
• Helget, L.N., O'Dell, J.R., Newcomb, J.A., Androsenko, M., Brophy, M.T., Davis-Karim, A., England, B.R., Ferguson, R., Pillinger, M.H., Neogi, T., others, . (2023). Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. Arthritis \& Rheumatology. Wiley Periodicals, Inc. Boston, USA.
• Choi, S., Mo, E., Sima, C., Wu, H., Thakkar-Samtani, M., Tranby, E., Frantsve-Hawley, J., Barrow, JR, . (2023). Impact of COVID-19 on Dental Care Utilization and Oral Health Conditions in the United States. JDR Clinical \& Translational Research. Page: 23800844231165016. SAGE Publications Sage CA: Los Angeles, CA.
• Schechter, M.S., Sabater-Anaya, N., Oster, G., Weycker, D., Wu, H., Arteaga-Solis, E., Bagal, S., McGarry, L.J., Van Brunt, K., Geiger, J.M. (2023). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis. Pulmonary Therapy. Page: 1--20. Springer Healthcare Cheshire.
• O’Dell, J.R., Brophy, M.T., Pillinger, M.H., Neogi, T., Palevsky, P.M., Wu, H., Davis-Karim, A., Newcomb, J.A., Ferguson, R., Pittman, D., others, . (2022). Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM evidence. Vol: 1, Issue: 3, Page: EVIDoa2100028. Massachusetts Medical Society.
• Stolzmann, K., Lew, R.A., Miller, C.J., Kim, B., Wu, H., Bauer, M.S. (2022). Does balancing site characteristics result in balanced population characteristics in a cluster-randomized controlled trial?. Health Services and Outcomes Research Methodology. Page: 1--10. Springer.
• Weisbord, S.D., Palevsky, P.M., Kaufman, J.S., Wu, H., Androsenko, M., Ferguson, R.E., Parikh, C.R., Bhatt, D.L., Gallagher, M. (2020). Contrast-associated acute kidney injury and serious adverse outcomes following angiography. Journal of the American College of Cardiology. Vol: 75, Issue: 11, Page: 1311--1320. American College of Cardiology Foundation Washington DC.
• Weycker, D., Hanau, A., Hatfield, M., Wu, H., Sharma, A., Bensink, M.E., Chandler, D., Grossman, A., Tarantino, M. (2020). Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. Journal of Medical Economics. Vol: 23, Issue: 2, Page: 184--192. Taylor \& Francis.
• Lew, R.A., Miller, C.J., Kim, B., Wu, H., Stolzmann, K., Bauer, M.S. (2019). A method to reduce imbalance for site-level randomized stepped wedge implementation trial designs. Implementation Science. Vol: 14, Issue: 1, Page: 1--9. BioMed Central.
• Boers, M., Singh, J.A., Cofield, S.S., Bridges, Jr, S.L., Moreland, L.W., O'Dell, J.R., Wu, H., Leatherman, S., Curtis, J.R. (2019). A novel method to combine assessment of benefit and harm: outcome measures in rheumatology 3$\times$ 3 methodology applied to two active comparator trials. Arthritis care \& research. Vol: 71, Issue: 2, Page: 319--322. Wiley Online Library.
• Kraja, A.T., Liu, C., Fetterman, J.L., Graff, M., Have, C.T., Gu, C., Yanek, L.R., Feitosa, M.F., Arking, D.E., Chasman, D.I., others, . (2019). Associations of mitochondrial and nuclear mitochondrial variants and genes with seven metabolic traits. The American Journal of Human Genetics. Vol: 104, Issue: 1, Page: 112--138. Elsevier.
• Timilsina, S., Brittan, K., O'Dell, J.R., Brophy, M., Davis-Karim, A., Henrie, A., Neogi, T., Newcomb, J., Palevsky, P., Pillinger, M., others, . (2018). Design and rationale for the veterans affairs “cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat” trial. Contemporary Clinical Trials. Vol: 68, Page: 102--108. Elsevier.
• Jovanova, O.S., Nedeljkovic, I., Spieler, D., Walker, R.M., Liu, C., Luciano, M., Bressler, J., Brody, J., Drake, A.J., Evans, K.L., others, . (2018). DNA methylation signatures of depressive symptoms in middle-aged and elderly persons: meta-analysis of multiethnic epigenome-wide studies. JAMA psychiatry. Vol: 75, Issue: 9, Page: 949--959. American Medical Association.
• Yao, C., Chen, G., Song, C., Keefe, J., Mendelson, M., Huan, T., Sun, B.B., Laser, A., Maranville, J.C., Wu, H., others, . (2018). Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nature communications. Vol: 9, Issue: 1, Page: 1--11. Nature Publishing Group.
• Weycker, D., Grossman, A., Hanau, A., Wu, H., Hatfield, M., Sharma, A., Bensink, M.E., Chandler, D., Tarantino, M.D. (2018). Immune thrombocytopenia in US clinical practice: incidence and healthcare utilization/expenditures in the first 12 Months following diagnosis. Blood. Vol: 132, Page: 2239. Elsevier.
• Weisbord, S.D., Gallagher, M., Jneid, H., Garcia, S., Cass, A., Thwin, S., Conner, T.A., Chertow, G.M., Bhatt, D.L., Shunk, K., others, . (2018). Outcomes after angiography with sodium bicarbonate and acetylcysteine. New England Journal of Medicine. Vol: 378, Issue: 7, Page: 603--614. Mass Medical Soc.
• Garcia, S., Bhatt, D.L., Gallagher, M., Jneid, H., Kaufman, J., Palevsky, P.M., Wu, H., Weisbord, S.D., Group, P.T. (2018). Strategies to reduce acute kidney injury and improve clinical outcomes following percutaneous coronary intervention: a subgroup analysis of the PRESERVE trial. JACC: Cardiovascular Interventions. Vol: 11, Issue: 22, Page: 2254--2261. American College of Cardiology Foundation Washington, DC.
• Yao, C., Chen, G., Song, C., Mendelson, M., Huan, T., Laser, A., Wu, H., Ho, J.E., Courchesne, P., Lyass, A., others, . (2017). Genome-wide association study of plasma proteins identifies putatively causal genes, proteins, and pathways for cardiovascular disease. bioRxiv. Page: 136523. Cold Spring Harbor Laboratory.
• Weycker, D., Bensink, M., Wu, H., Doroff, R., Chandler, D. (2017). Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Current Medical Research and Opinion. Vol: 33, Issue: 12, Page: 2115--2120. Taylor \& Francis.
• Weycker, D., Li, X., Barron, R., Wu, H., Morrow, P.K., Xu, H., Reiner, M., Garcia, J., Mhatre, S., Lyman, G. (2015). Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN. Cancer Research. Vol: 75, Issue: 9\_Supplement, Page: P6--10. AACR.
• Weycker, D., Li, X., Barron, R., Wu, H., Morrow, P., Xu, H., Reiner, M., Garcia, J., Mhatre, S.K., Lyman, G.H. (2015). Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use. Journal of the National Comprehensive Cancer Network. Vol: 13, Issue: 8, Page: 979--986. Harborside Press, LLC.
• Weycker, D., Li, X., Barron, R., Wu, H., Morrow, P.K., Xu, H., Reiner, M., Garcia, J., Mhatre, S., Lyman, G.H. (2014). Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”. Blood. Vol: 124, Issue: 21, Page: 4824. Elsevier.
• Edelsberg, J., Weycker, D., Barron, R., Li, X., Wu, H., Oster, G., Badre, S., Langeberg, W.J., Weber, D.J. (2014). Prevalence of antibiotic resistance in US hospitals. Diagnostic microbiology and infectious disease. Vol: 78, Issue: 3, Page: 255--262. Elsevier.
• Weycker, D., Wu, H., Hagiwara, M., Li, X., Barron, R.L. (2014). Use of chemotherapy and same-day pegfilgrastim prophylaxis in US clinical practice. Blood. Vol: 124, Issue: 21, Page: 4825. Elsevier.
• O'Seaghdha, C.M., Wu, H., Yang, Q., Kapur, K., Guessous, I., Zuber, A.M., K\"ottgen, Anna, ., Stoudmann, C., Teumer, A., Kutalik, Zolt\'an, ., others, . (2013). Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations. PLoS genetics. Vol: 9, Issue: 9, Page: e1003796. Public Library of Science San Francisco, USA.
• Werner, M., Russo, J., Wu, H., Rilett, D., Ahrabi, A., Grove, L., Dow, D., Valverde, P. (2013). The Current \& Future Vision Making Wentworth even better.
• O'Seaghdha, C.M., Yang, Q., Wu, H., Hwang, S., Fox, C.S. (2012). Performance of a genetic risk score for CKD stage 3 in the general population. American journal of kidney diseases. Vol: 59, Issue: 1, Page: 19--24. Elsevier.
• LeBlanc, M., Rilett, D., Russo, J., Werner, M., Wu, H. (2011). Introducing bioinformatics into the computer science curriculum: panel discussion. Journal of Computing Sciences in Colleges. Vol: 26, Issue: 6, Page: 130--132. Consortium for Computing Sciences in Colleges.
• Yang, Q., Wu, H., Guo, C., Fox, C.S. (2010). Analyze multivariate phenotypes in genetic association studies by combining univariate association tests. Genetic epidemiology. Vol: 34, Issue: 5, Page: 444--454. Wiley Online Library.

Conference Proceedings

• Helget, L., Davis-Karim, A., O'Dell, J., Mikuls, T., Newcomb, J., Androsenko, M., Brophy, M., England, B., Ferguson, R., Pillinger, M., others, . (2022). Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study: ARTHRITIS \& RHEUMATOLOGY. Vol: 74, Page: 3616--3618.
• Helget, L., O'Dell, J., Newcomb, J., Androsenko, M., Brophy, M., Davis-Karim, A., England, B., Ferguson, R., Pillinger, M., Neogi, T., others, . (2022). Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post-Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial: ARTHRITIS \& RHEUMATOLOGY. Vol: 74, Page: 3553--3555.
• Helget, L., O'Dell, J., Newcomb, J., Androsenko, M., Brophy, M., Davis-Karim, A., England, B., Ferguson, R., Pillinger, M., Neogi, T., others, . (2022). Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial: ARTHRITIS \& RHEUMATOLOGY. Vol: 74, Page: 3129--3131.
• Deligiannidis, L., Yu, C., Yun, M., Wu, H. (2019). Case Study: Skymap Data Analysis: Proceedings on the International Conference on Artificial Intelligence (ICAI). Page: 54--59.
• Chen, K., Qin, S., Weycker, D., Wu, H., Vera-Llonch, M., Krasner, A., Remkus, L., Oster, G. (2017). Economic Burden of Chronic Hypoparathyroidism in US Clinical Practice: 99th Annual Meeting of the Endocrine Society.
• Lew, R., Wu, H., Yu, C. (2017). Integrating Human Input for Decision Making with Informative Bayesian Beliefs: 2017 AAAI Spring Symposium Series.
• Lew, R., Wu, H., Miller, C., Kim, B., Bauer, M.S. (2016). Balancing Site Characteristics for Stepped Wedge Designs.: 2016 Annual Research Meeting.
• Weycker, D., Li, X., Barron, R., Wu, H., Morrow, P.K., Xu, H., Reiner, M., Garcia, J., Mhatre, S., Lyman, G. (2015). Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN: CANCER RESEARCH. Vol: 75, Issue: 9.
• Leatherman, S., Wu, H., Keystone, E., Brophy, M., O'Dell, J. (2014). Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept: ARTHRITIS \& RHEUMATOLOGY. Vol: 66, Page: S1033--S1033.
• Lew, R., Rybin, D., Hannagan, K., Wu, H., Keystone, E., Mikuls, T.R., O'Dell, J. (2014). Follow-up Data on the Rheumatoid Arthritis Comparison of Active Therapies Trial: Observational Cohort.: ARTHRITIS \& RHEUMATOLOGY. Vol: 66, Page: S670--S671.
• Weycker, D., Chandler, D., Barron, R., Xu, H., Wu, H., Girardi, V., Edelsberg, J., Lyman, G.H. (2013). Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin's Hodgkin's Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice: BLOOD. Vol: 122, Issue: 21.
• Gagnon, D.R., Wu, H., Cho, K., Lawler, E.V. (2012). Obtaining Risk Ratios from Regression Models: A Cautionary Tale: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. Vol: 21, Page: 125--125.

Other

• Wu, H. (2009). Methods for Genetic Association Studies Using Longitudinal and Multivariate Phenotypes in Families. Boston University.